Prevention · Screening · Early detection

HPV and Hepatitis B Vaccination

Some cancers begin with infections that vaccination can prevent. The right vaccine schedule depends on age, immune status, product and programme.

Chapter 13 of 16

13 of 16
Choose a chapter

Key facts

  • HPV vaccination works best before exposure.
  • Vaccines do not treat established HPV or hepatitis B infection.
  • Cervical screening remains important after HPV vaccination.

From information to action

Practical discussion checklist
ActionHow to use it
Bring vaccine records and mention immune-suppressing treatment.Discuss feasibility and any relevant medical conditions with your healthcare team.
Ask the vaccinator to record the product and remaining schedule.Discuss feasibility and any relevant medical conditions with your healthcare team.
Arrange pregnancy-related HBV assessment and timely newborn protection.Discuss feasibility and any relevant medical conditions with your healthcare team.
Continue cervical screening after HPV vaccination.Discuss feasibility and any relevant medical conditions with your healthcare team.

Choose the right next step

  1. New or concerning symptoms? Arrange diagnostic assessment. Severe bleeding, breathlessness or new neurological weakness needs urgent care.
  2. No symptoms, but previous cancer, precancer or increased inherited risk? Ask for an individual surveillance plan; average-risk intervals may not apply.
  3. No such history? Use this chapter to discuss prevention and, where appropriate, age- and test-specific screening. Lifestyle exposures alone do not establish eligibility for every test.
  4. After testing: Collect the result, complete any referral, and record the next review date. A normal screen does not explain a later symptom.

Which cancers can vaccination help prevent?

HPV is associated with cervical, anal, penile, vulvar, vaginal and some oropharyngeal cancers. Vaccines protect against selected HPV types, not every cancer-causing infection. Bivalent vaccines target types 16 and 18; quadrivalent products also cover 6 and 11, and nonavalent products cover additional high-risk types. Protection is strongest when vaccination occurs before infection.

WHO schedules and immune status

WHO 2022 supports one or two doses for girls aged 9–14 and girls/women aged 15–20, with two doses six months apart for older age groups under its programme guidance. People who are immunocompromised or living with HIV need at least two doses and, where feasible, three. The simplified schedule must not be applied indiscriminately to every vaccine recipient; follow the actual programme and product guidance.

Catch-up, boys and international differences

HPV vaccination can benefit boys as well as girls. US CDC guidance routinely vaccinates at 11–12, permits starting at 9, and recommends catch-up through 26; ages 27–45 involve shared decision-making rather than universal catch-up. Under that schedule, starting before 15 usually means two doses 6–12 months apart, while starting at 15 or later or being immunocompromised generally means three at 0, 1–2 and 6 months. These US schedules are not identical to WHO population-programme advice or Indian product labels.

India’s programme and practical questions

India launched a nationwide voluntary, free single-dose HPV campaign for 14-year-old girls on 28 February 2026 at government facilities with consent. Confirm current local eligibility, vaccine availability and arrangements at the primary-care centre. This campaign does not imply that boys or adults receive the same publicly funded schedule. A clinician can discuss other age groups and licensed products privately where appropriate.

Safety, pregnancy and missed doses

Common effects include injection-site pain and short-lived fever; fainting can occur around injections. Report a history of severe allergic reaction to a vaccine component. HPV vaccination is usually deferred during pregnancy; inadvertent vaccination is not by itself an indication to end a pregnancy. A delayed series generally does not need restarting, but the vaccinator should confirm the remaining doses. Vaccination does not replace screening or treatment of existing lesions.

Hepatitis B vaccination and liver cancer

Preventing chronic HBV reduces a major cause of cirrhosis and hepatocellular carcinoma. WHO recommends a birth dose within 24 hours followed by completion of the infant series. India’s routine schedule includes the birth dose and hepatitis B-containing infant doses. Unvaccinated adults, including health workers, household or sexual contacts of infected people and people with exposure risks, should discuss testing and vaccination. Dialysis and immunocompromised patients may need different doses and response checks.

Chronic infection requires continuing care

A vaccine does not clear established hepatitis B. HBsAg and other tests help establish infection and immunity in an appropriate clinical setting. People with chronic HBV need liver assessment, antiviral treatment when indicated and liver-cancer surveillance when eligible, even if they feel well. Partners and household contacts should be assessed. Use sterile equipment and do not share needles or blood-contaminated razors; ordinary social contact does not justify isolation.

Practical steps

  • Bring vaccine records and mention immune-suppressing treatment.
  • Ask the vaccinator to record the product and remaining schedule.
  • Arrange pregnancy-related HBV assessment and timely newborn protection.
  • Continue cervical screening after HPV vaccination.

Myth and fact

One HPV schedule fits every age and immune status.

False. Programme recommendations, age, product and immune status change the schedule.

Frequently asked questions

Can HPV vaccination cure an abnormal Pap result?

No. The abnormal result still needs its own follow-up.

Does hepatitis B vaccination replace treatment for chronic HBV?

No. Established infection needs assessment, and some people need antivirals and cancer surveillance.

Continue learning

Sources and guideline context